S2 File - Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver disease: A multilevel linear regression analysis at Va... by Sonsawan Sangprasert (22772538)

Map of Zimbabwe highlighting the districts detected as persistent hotspots of <i>S. haematobium</i> prevalence (PPHS), persistent hotspots of decreased praziquantel efficacy (EPHS)... by Takafira Mduluza (39754)

Box plots showing baseline prevalence and mean egg count at pre-MDA1 in districts that were responders compared to those that were persistent hotspots of decreasing praziquantel ef... by Takafira Mduluza (39754)

Fecal egg count reduction percentage (FECRP). by Sohail Afzal (10850709)

“…EPG values were used to determine the fecal egg count reduction (FECR). Statistically, there was a significant decrease in EPG values from days 0–14. …”

Distribution of continuous variables of all 3 visits of group 1 (placebo) and group 2 (placebo) that have no significant difference among the groups. by Nattapon Riengvirodkij (11268720)

Subjects:

Decreasing oxygen saturation with corresponding levels of NLR and D-dimer for understanding the interplay of inflammation. by Narendran Gopalan (110148)

<i>e-lgp</i> curve of improved red clay. by Quan Shen (37564)

“…The indicate reveal that: (1) the addition of RoadyesTM alone results in a reduction in both the liquid limit and plasticity index, while simultaneously increasing cohesion and unconfined compressive strength; (2) Red clay treated with 0.25% RoadyesTM demonstrates the highest compression index, indicating optimal compressibility.; (3) The combination of RoadyesTM with cement and lime significantly enhances the mechanical properties of the red clay. …”

Degeneration Saline group presented with significant decreased final weight in relation to other groups. by Flavia Gomes Velasque Gama (21175112)

Aripiprazole significantly decreases phosphorylated Src (Y416) levels in dHL-60 cells. by Courtney A. Swain (15170264)

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

Subjects:

Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Map of Harlingen, TX showing the location of the four study neighborhoods. by Jesús A. Aguilar-Durán (9931967)

Subjects:

<i>Aedes aegypti</i> database from SAGO traps. by Jesús A. Aguilar-Durán (9931967)

Subjects: